Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I nivolumab + niraparib for solid tumors with chromothripsis
jRCT2041240201Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and niraparib in Nonhematologic neoplasms and cancer (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Mar 2025; status: recruiting.
02
Drugs
nivolumabniraparib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2041240201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240201.